Department of Experimental Biology, University of Jaén, Paraje Las Lagunillas s/n, 23071, Jaén, Spain.
Mol Cell Biochem. 2012 Apr;363(1-2):101-8. doi: 10.1007/s11010-011-1162-1. Epub 2011 Dec 7.
We previously reported that treatment with a single dose of deferoxamine (DFO), which acts as a hypoxic-mimetic agent, only induces reactive oxygen species (ROS) production in the presence of poly(ADP-ribose) polymerase (PARP-1). Given that mitochondria are one of the main sources of ROS, the present study was designed to assess the effect of DFO treatment on the activity of mitochondrial respiratory chain complexes, and more importantly, to determine whether this effect is modulated by PARP-1. We found that DFO treatment induced a progressive decline in complex II and IV activity, but that this activity was preserved in PARP-1 knock-out cells, demonstrating that this decrease is mediated by PARP-1. We also confirmed that complex II inhibition after DFO treatment occurs in parallel with poly-ADP ribosylation. Consequently, we recommend that PARP-1 activation be taken into account when using DFO as a hypoxia-mimetic agent, because it mediates alteration of the mitochondrial respiratory chain.
我们之前曾报道过,单次使用铁螯合剂去铁胺(DFO)治疗只会在聚(ADP-核糖)聚合酶 1(PARP-1)存在的情况下诱导活性氧(ROS)的产生。鉴于线粒体是 ROS 的主要来源之一,本研究旨在评估 DFO 处理对线粒体呼吸链复合物活性的影响,更重要的是,确定这种影响是否由 PARP-1 调节。我们发现 DFO 处理诱导复合物 II 和 IV 活性逐渐下降,但在 PARP-1 敲除细胞中这种活性得到了保留,表明这种下降是由 PARP-1 介导的。我们还证实,DFO 处理后复合物 II 的抑制与多聚 ADP 核糖化平行发生。因此,我们建议在将 DFO 用作缺氧模拟物时考虑 PARP-1 的激活,因为它介导了线粒体呼吸链的改变。